← Eichor
Condition: Higher Risk Myelodysplastic Syndromes Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Higher Risk Myelodysplastic Syndromes

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Prolonged Ultra Low-dose Decitabine Plus Venetoclax for Primary Diagnosed Elderly AMLK/MDS
Phase 2 · 1 location(s) · First Affiliated Hospital of Zhejiang University · NCT06046313Ivosidenib as Maintenance Therapy in Transplant-Ineligible IDH1-mutated AML and HR-MDS
Phase 2 · 1 location(s) · Ruijin Hospital · NCT07607418Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leuk
Phase 1/Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT04140487Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
Phase 2 · 1 location(s) · Masonic Cancer Center, University of Minnesota · NCT03314974VA Conditioning Regimen Allo-HSCT for Elderly Higher-risk MDS
Phase 1/Phase 2 · 1 location(s) · Navy General Hospital, Beijing · NCT06471946Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant
Phase 1/Phase 2 · 1 location(s) · Fred Hutchinson Cancer Center · NCT06928662Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myel
Phase 2 · 143 location(s) · National Cancer Institute (NCI) · NCT06577441Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies
Phase 1/Phase 2 · 1 location(s) · Beijing Biotech · NCT07523555Clinical Study of Azacitidine Combined With Ruxolitinib in the Treatment of Higher-risk MDS/MPN
Phase 2 · 1 location(s) · The First Affiliated Hospital with Nanjing Medical Universit · NCT05817955(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
Phase 2 · 42 location(s) · Cogent Biosciences, Inc. · NCT04996875Venetoclax-containing Therapy Combined With Microtransplant for Intermediate-risk and Higher MDS
Phase 2 · 1 location(s) · Beijing 302 Hospital · NCT07238686A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias
Phase 1 · 11 location(s) · Crossbow Therapeutics, Inc. · NCT06994676A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome
Phase 1 · 13 location(s) · BlossomHill Therapeutics · NCT06501196A Study of AK117 in Combination With Azacitidine in Patients With Myelodysplastic Syndromes
Phase 2 · 15 location(s) · Akeso · NCT06196203Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Pati
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT00801489First-in-human (FIH) Trial of GEN3018 in Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-risk Myelod
Phase 1 · 6 location(s) · Genmab · NCT07384715A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT05365035Combining Active and Passive DNA Hypomethylation
Phase 2 · 10 location(s) · Kirsten Grønbæk · NCT03999723Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory A
Phase 1/Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT04047641Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hem
Phase 2 · 1 location(s) · Fred Hutchinson Cancer Center · NCT07046078Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hem
Phase 2 · 1 location(s) · Fred Hutchinson Cancer Center · NCT06013423CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relap
Phase 1 · 1 location(s) · Fred Hutchinson Cancer Center · NCT04375631Safety and Proof-of-Concept Study of RPT1G in Adults With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes
Phase 1 · 2 location(s) · Remedy Plan, Inc. · NCT07107126ONC201 in Treating Patients With Relapsed or Refractory Acute Leukemia or High-Risk Myelodysplastic Syndrome
Phase 1/Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT02392572ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute My
Phase 1/Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT05010122Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Maligna
Phase 1/Phase 2 · 30 location(s) · AstraZeneca · NCT07155226Optimization of Post-transplantation Benadamustine and Cyclophosphamide in Patients With High-risk Myeloid Malignancies
Phase 2 · 1 location(s) · St. Petersburg State Pavlov Medical University · NCT07238712CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT04493164VA Combined With PD-1 Inhibitor for the Treatment of Relapsed and Refractory AML and High-risk MDS
Phase 2 · 1 location(s) · Beijing 302 Hospital · NCT06536959Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT03589729
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.